Abstract: Heart failure (HF) is very common in the general population and specifically in CKD patients due to higher prevalence of traditional and CKD-related risk factors. In particular, HF with preserved ejection fraction (HFpEF) can affect over 50% of dialysis patients. However, little is known about this entity in CKD. It has been inadequately recognized over time and few data exist regarding clinical profiles and outcomes in dialysis patients. The aim of this paper is to do a critical appraisal of the diagnosis, clinical impact, and management of HFpEF with a focus on new diagnostic criteria and its impact on dialysis.
Heart failure (HF) is one of the most frequent complications and the leading cause of cardiovascular mortality in patients with advanced CKD (1) . In fact, the risk of cardiovascular mortality is more than 10 times higher in this population compared with an age-, sex-, and race-matched population (2) . There are several reasons: risk factors for HF, such as coronary heart disease, diabetes, obesity, and hypertension are frequently present in patients with CKD who are also subject to CKD-related risk factors such as inflammation, increased calcium and phosphorus levels, uremic toxins, anemia, fluid overload, Arteriovenous (AV) fistulae, and ischemic injury from intradialytic hypotension (IDH) ( Fig. 1) (2) .
Clinically, HF is classified into two major types based on the heart functional status: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). HFpEF refers to a clinical syndrome in which patients have symptoms and signs of HF, normal or near normal left ventricular (LV) systolic function (ejection fraction [EF] over 50%), and evidence of diastolic dysfunction (DD), for example, abnormal LV filling and elevated filling pressure (3) . This form of HF has become increasingly recognized and has a huge impact in CKD patients. Yet, despite a high prevalence of this disease, to our knowledge, few data exist regarding the clinical profiles and outcomes associated with HFpEF in CKD patients. It is important to differentiate the clinical profile and prognosis of dialysis patients with HFpEF or HFrEF because of the different therapeutic strategies required for the two types of HF (1) .
EPIDEMIOLOGY
CKD patients are more than twice as likely to have cardiovascular disease compared to non-CKD patients. According to the USRDS Annual Data Report, nearly 40% of patients with stage 4-5 CKD carried a diagnosis of HF in 2015 (4) . Due to a variety of factors, CKD and HFpEF are becoming more prevalent. Whether due to a common etiology or arising independently, CKD and HFpEF are often coincident in patients. Furthermore, the population with both problems is expanding. Studies published 10 years ago found that renal dysfunction is associated with worse outcomes and higher mortality in HFpEF patients. Despite the association between CKD and adverse outcomes, the interplay between CKD, clinical characteristics, and cardiac structural and functional abnormalities in HFpEF have not been well described (6) .
PATHOPHYSIOLOGY
Essentially there are two pathophysiological models of HFpEF: the traditional and the emerging model, which are not mutually exclusive. The main pathophysiological perturbation leading to HFpEF remains incompletely defined, but traditionally it has been attributed to hypertensive LV remodeling (7) .
In the traditional pathophysiological model, pressure overload leads to concentric LV hypertrophy, fibrotic remodeling, and DD. Ultimately, left ventricular diastolic dysfunction (LVDD) leads to left atrial (LA) hypertension and remodeling, pulmonary venous hypertension, and right ventricular and atrial remodeling (Fig. 2) . Therefore atrial fibrillation (AF) is common because of the chronic LA hypertension and subsequent structural and electrical remodeling (7) .
In the emerging model, proinflammatory cardiovascular and noncardiovascular coexisting conditions lead to systemic microvascular endothelial inflammation, global cardiac and skeletal-muscle inflammation, and subsequent fibrosis (Fig. 3) . Thus, systemic microvascular endothelial inflammation has been proposed as an additional mechanism leading to myocardial inflammation and fibrosis, increasing oxidative stress and promoting alterations in cardiomyocyte signaling pathways. These changes promote cardiomyocyte remodeling as well as microvascular dysfunction in cardiac and skeletal muscle (7). In CKD, there are several conditions contributing to the pathogenesis of HFpEF, such as arterial hypertension (3) . Left ventricular hypertrophy (LVH) is also one of the major myocardial changes in CKD and CKD itself plays an important role in its development. It develops early in the progression of kidney dysfunction, is frequently accompanied by myocardial fibrosis and DD, and is an independent risk factor for mortality in this population. The role of CKD is well documented but more obscure in its basis. The effect of uremia on the myocardium includes structural changes such as cardiomyocyte hypertrophy, myocardial fibrosis, and thickening of the intramural arteries. Together, these structural changes predispose to DD in response to a cumulative action of traditional and CKD-related risk factors (8) (9) (10) (11) . On one hand, there is good evidence that interstitial fibrosis is related to changes in collagen myocardial metabolism. On the other hand, cardiomyocyte hypertrophy and vascular remodeling may be an adaptive response to pressure and volume overload (8) .
There are numerous relevant hemodynamic changes applicable to the dialysis population. Preload-related factors involve expansion of intravascular volume, anemia, and high-flow arteriovenous fistulas created for vascular access in HD patients. Afterload-related factors include systemic arterial resistance (systolic and diastolic hypertension) and large-vessel compliance (vascular calcification), resulting in myocardial cell thickening and concentric LV remodeling (3) . Others, such as hyperphosphatemia, hyperparathyroidism, and hypovitaminosis D play a greater role in more advanced stages of CKD and dialysis (12, 13) . Another important factor is the activation of the renin-angiotensin-aldosterone system (RAS), potentially inducing myocardial fibrosis and hypertrophy. Activation of the intracardiac RAS seems to be critically involved in overload status observed in dialysis, but angiotensin II and aldosterone can also be involved in myocardial cell hypertrophy and fibrosis independent of afterload (14) .
New approaches to analyze the mechanisms by which DD develops in CKD stage 5 and in ESRD have emerged. Much attention has been focused on the novel cellular mediator systems that translate hemodynamic and circulatory alterations. These cellular systems, potentially involved in DD, include vitamin D receptor (VDR) activation, calcineurin/nuclear factor of activated T cells, G-protein-coupled receptor to angiotensin II and endothelin 1 and the mammalian target of rapamycin (mTOR) pathway (14) . Further understanding of these mechanisms will be important for the development of effective therapeutic strategies.
DIAGNOSIS
The diagnosis of HFpEF is presented in Figure 4 . According to the new recommendations for evaluation of left diastolic function from the American Society of Echocardiography and the European Association of Cardiovascular Imaging there are five recommended variables identifying DD. The cutoff values are presented in Figure 4 . LVDD is present if more than half of the available parameters meet the cutoff values (15) .
However, it is important to note that the echocardiographic evaluation of DD is dependent on transmitral flow, annular tissue Doppler, LA volume and pulmonary vein flow -all volume-dependent variables (16) . So, echocardiography can be an imperfect technique, particularly in dialysis patients due to the fact that it is dependent on the preload conditions. Therefore, the echocardiogram must be performed and interpreted carefully and, if possible, done on nondialysis days, where volume overload may be less evident (17) .
Besides echocardiogram parameters, objective evidence of DD should also include electrocardiography, chest radiography, and measurement of cardiac biomarkers such as pro-BNP (pro-brain natriuretic peptide) (7). However, natriuretic peptide levels must be interpreted with caution. They may be elevated in dialysis for several reasons: first, it increases with deteriorating renal function; second, pro-BNP is secreted in response to increases in myocardial wall stretch and its measurement is volume status dependent; third, HD may partially clear and reduce pro-BNP levels (18) . Finally, right heart catheterization may be required in patients in whom there is indeterminate noninvasive testing or evidence of pulmonary hypertension (7).
INTERVENTION AREAS Normal renal function patients
Among patients with diastolic HF, few data are available to guide the treatment, even in patients with normal renal function. In contrast to HFrEF there are limited clinical trials guiding the treatment of HFpEF. In fact, medications that improve outcomes in patients who have HFrEF have not shown to be of benefit in those who have HFpEF, which suggest that the fundamental differences in the pathophysiology underlying HFrEF vs. HFpEF are clinically consequential (7, 19) . Management of these patients is based on factors that may contribute to DD, such as hypertension, heart rate control, blood volume, and myocardial ischemia (Fig. 5) . Currently, no specific therapy has demonstrated a mortality benefit in patients with HFpEF. Calcium channel blockers, beta blockers, angiotensin receptor blockers (ARBs), and angiotensin-converting-enzyme (ACE) inhibitors are frequently used in patients with HFpEF because of concomitant cardiovascular diseases. Dialysis modality-specific challenges In dialysis, cardiovascular disease is the leading cause of mortality. When comparing HD with Peritoneal Dialysis (PD), there are some pathophysiological mechanisms and risk factors that are common to both techniques, however, each one has its particularities and contributions to HFpEF, as shown in Figure 6 .
The HD procedure itself promotes cardiomyopathy by inducing hypotension and episodic regional cardiac ischemia that promotes global dysfunction, fibrosis, worsening symptoms, and increased mortality. These postischemic events are known as myocardial stunning and represent a form of ischemia-reperfusion injury. Repetitive episodes of ischemia are cumulative and eventually lead to cardiac fibrosis (20) . Current literature attributes the effect of the typical concentric LVH on IDH to both hemodynamic factors and structural factors, such as valvular degeneration. First, patients with concentric LV are particularly sensitive to abrupt changes in cardiac loading status, predisposing them to prominent blood pressure fluctuation during ultrafiltration (21) . This phenomenon stems from the fact that LV stiffening and reduction in compliance is associated with elevation of end-diastolic pressure. As filling of LV becomes difficult during dialysis, even low levels of volume reduction could translate into wide variations in cardiac output and then BP. This has been found to be the major etiology of LVH-related IDH, which is the base of the DD theory (22) . So, HFpEF leads to IDH which leads to more ischemic injury, becoming a vicious circle. Second, the presence of LVH is frequently associated with the occurrence of aortic stenosis, as well as higher myocardial injury, represented by elevated plasma cardiac troponin I. Prolonged aortic stenosis could expectedly lead to hemodynamic instability, precipitating IDH episodes. Third, the cyclical character of HD eventually leads to cyclic acid-base and ionic changes, which may contribute to cardiac dysfunction (20) .
Comparing to PD there are several differences, namely metabolic issues such as dysmetabolism and obesity which can further influence cardiovascular risk profiles in PD patients (23) . The majority of PD solutions are glucose-based and most of PD cardiovascular concerns have traditionally been attributed to PD glucose solutions, especially in diabetic patients (24) . The high glucose load associated with PD may lead to insulin resistance and to the development of an atherogenic lipid profile (25) . However, a Portuguese study highlighted the fact that obesity is indeed associated with insulin resistance in PD patients, independently of peritoneal glucose absorption and fast transport status, indicating that glucose is not necessarily the major problem in the cardiovascular profile of PD patients (26) . Also, volume control is an important predictor of outcome in chronic PD patients. Salt and fluid removal constitutes a key component in the cardiovascular management of PD patients (27) . Despite causing less myocardial stunning due to continuous ultrafiltration during 24 h and less ionic and acid-base changes, PD chronic fluid overload may contribute to cardiovascular mortality in these patients (24) .
Specific intervention areas for HFpEF and DD in dialysis are lacking.
The approach for prevention and treatment of LVH and HFpEF in CKD and ESRD must be multilevel and properly grounded in fundamental principles of pathophysiology. Recognition of the main risk factors-fluid overload and elevated blood pressure-is crucial (28) .
An important caveat is the aforementioned excessive susceptibility to excessive preload reduction, which can sequentially lead to the underfilling of the LV, drop in cardiac output, hypotension and also create subaortic outflow obstruction, especially in severe LVH (3). For these reasons, a valid alternative for these kind of patients is more frequent or longer HD sessions, such as in nocturnal dialysis or daily HD. In fact, excellent blood pressure control is achieved with nocturnal HD. Some studies suggest that nocturnal HD is associated with regression of LVH (29) (30) (31) . As an example, in a study of 44 patients undergoing maintenance HD who were randomly assigned to nocturnal HD (six times/ week) or continued conventional HD (three times/ week) (30), at 6 months, LV mass had significantly decreased with nocturnal HD (177-164 g) compared with no change in the conventional HD group (182-183 g). Concerning cardiac function, limited evidence suggests that the switch to nocturnal HD may improve myocardial function as assessed by EF. In one small study, for example, cardiac function improved upon conversion to nocturnal HD in a group of six patients with ESRD and diminished LV EF (32) . EF increased from 28% to 41%. In another study, intradialytic LV regional wall motion abnormalities (myocardial stunning) decreased with increasing dialysis intensity, favoring daily and nocturnal HD (33) . Myocardial stunning is associated with high ultrafiltration requirements, IDH, longterm loss of systolic function, increased likelihood of cardiovascular events, and death (33) . In contrast, the administration of diuretics or venodilators such as nitrates, dihydropyridine calcium channel blockers, and ACE inhibitors must be done with caution (3).
Pharmacologic interventions and management of contributing comorbidities
An important component of treating a patient with HFpEF (whether on dialysis or not) is to treat the contributing factors and comorbidities that are frequently present and have impact on the clinical course. The most common are hypertension, lung disease, coronary artery disease, AF, obesity, anemia, diabetes mellitus, kidney disease, and sleep disorders. These comorbidities should be treated according to current guidelines, and have an important impact on the clinical course and in the majority of subsequent hospitalizations in patients with HFpEF (34) .
For example, blood pressure control is very important and has beneficial effects on LVH in ESRD patients (3) . Concerning pharmacological measures to treat hypertension only β-blockers and nondihydropyridine calcium channel blockers have proven effectiveness in reducing the incidence of IDH in patients with LVH and DD (35) . In contrast, although ACE inhibitors play an important role in treating the disease processes that contribute to the development of HFpEF, namely hypertension (reduction in systemic pressure can theoretically lead to regression of LVH and a gradual improvement in diastolic function), coronary heart disease, and diabetes, there are controversial results regarding its benefits in preserving residual kidney function (RKF) and therefore improving HF (36, 37) . A recent randomized, controlled trial of 42 HD patients found that ACE inhibition therapy was associated with greater RKF preservation compared with control, with RKF defined as residual Glomerular Filtration Rate (GFR) and urine volume. However, another observational study found no difference in the use of ACE inhibitors for RKF, defined by residual creatinine clearance. Given the different definitions of RKF used in each study, interpretation should be done with caution to avoid direct comparison (38) .
In addition to its importance treating hypertension, there are other pharmacological measures that can contribute to LVH regression and that can improve DD, namely ACE inhibitors, ARBs, direct renin inhibitor (aliskiren), some calcium channel blockers (particularly diltiazem, verapamil, and amlodipine), and some sympatholytic agents (including methyldopa and alpha-blockers) (39) (40) (41) (42) (43) . Regression of LVH continues gradually over time and may be associated with a complete reversal of LVH and other abnormalities induced by hypertension such as LA enlargement and DD (40) . By contrast, regression may be less pronounced with diuretics and beta blockers and is largely absent with direct vasodilators (such as hydralazine or minoxidil) and some calcium channel blockers, despite adequate blood pressure control (36) . The ineffectiveness of direct vasodilators probably reflects the reflex stimulation of norepinephrine and angiotensin II release induced by these drugs since these hormones may directly promote the development of LVH (36) .
So, current recommendations point to the use of either an angiotensin-converting enzyme inhibitor or ARB as a first-line agent followed by a β-blocker or a combined β-and α-blocker, because most ESRD patients have cardiovascular disease (35) . However, there is still a lack of direct evidence to support a specific drug regimen to treat Diastolic Heart Failure (DHF) in the ESRD population.
Another pharmacological intervention with potential antifibrotic action involves a class of aldosterone block receptors (spironolactone). Studies conducted in CKD patients (44) and in animal models of uremic myocardiopathy suggested an important antifibrotic effect of spironolactone, resulting in a reduction in LV mass and improvement of arterial stiffness that is likely independent of blood pressure control (45) . One common problem with these drugs is the development of hyperkalemia, limiting more widespread spironolactone use in CKD patients, particularly those in advanced stages of CKD. In a small nonrandomized and nonblinded clinical study in HD patients, low-dose spironolactone (25 mg, 3 times/week) was not associated with more frequent hyperkalemia during the 8-week follow-up (46) .
Other interesting approaches (although primarily based on preliminary experimental observations) to attenuate DHF in CKD patients deserve attention. Torsemide is a loop diuretic with potential myocardial antifibrotic action. Unlike furosemide, it may decrease myocardial collagen accumulation (47) . In addition, LV mass decreases in renal transplant patients with LVH when converted to a sirolimus-based regimen (48), independently of better blood pressure control. In animal models, this effect appears to involve the mTOR pathway.
Besides hypertension, there are other key principles in the treatment of LVH in dialysis patients such as anemia and management of secondary hyperparathyroidism. The impact of anemia therapy (with erythropoiesis-stimulating agents) on LVH in CKD and/or ESRD has been examined in several randomized controlled trials but most of them have failed to show any beneficial effect. Parfrey et al. (49) reported a meta-analysis of 15 trials and showed how LV mass was reduced by anemia correction only in those subjects who had severe anemia at baseline (<10 g/dL) and who were treated to a lower target hemoglobin level (<12 g/dL). Chen et al. (50) compared the effects of epoetin alfa vs. darbepoetin alfa on LVH in subjects with CKD. Both agents were equally effective in lowering LV mass. The correction of severe anemia (hemoglobin <10 g/dL) with erythropoiesis-stimulating agents seems to attenuate LVH progression (51) , but the achievement of hemoglobin levels >12 g/dL does not help reduce the LV mass.
The correction of abnormalities in divalent ion metabolism in CKD and ESRD (including vitamin D deficiency, hyperphosphatemia, and hyperparathyroidism) might have beneficial effects on LVH (52) . Activation of VDRs may also play a role in the prevention and treatment of DHF. Dialysis and nondialysis patients receiving vitamin D therapy seem to have a lower frequency of cardiovascular events and improved survival (53), by mechanisms not only related to mineral metabolism control, but also probably related to VDR activation in cardiovascular tissue (54) . Several studies in the dialysis population, using activated and nonactivated (nutritional) vitamin D have been conducted with cardiovascular endpoints. In patients with secondary hyperparathyroidism on HD, intravenous calcitriol caused regression in myocardial hypertrophy and improved cardiac systolic and diastolic function (55) . Indeed, vitamin D deficiency is highly prevalent among the dialysis and nondialysis population (56, 57) and its supplementation with cholecalciferol is associated with a reduction in LV mass index and attenuation of systemic inflammation (58) .
Also, restoration and maintenance of sinus rhythm are preferred when AF occurs in patients with DHF. When this cannot be achieved, rate control becomes essential (3) . The addition of a cardioselective beta-blocker (such as carvedilol) may be appropriate for those subjects with moderate to severe LVH at risk for ventricular arrhythmias, but this needs to be tested further in larger controlled trials. Implantable automated defibrillators may be appropriate for a small subset of ESRD patients who survive an initial episode of ventricular fibrillation, but this approach may not be very cost-effective. Prevention of the substrate for potentially fatal cardiac arrhythmias is the best path to take (28) .
Kidney transplantation
Kidney transplantation (KT) recipients have demonstrated an improved survival and a significant reduction in LVDD rates after the KT. It may be caused by resolved occult volume overload, restoring renal function, interrupting the ongoing stressors related to dialysis, as well as improving other mediators of HF such as anemia and inflammatory markers (59, 60) . Despite the potential benefits of KT on cardiac function, cardiovascular death remains the most frequent cause of death in KT recipients. One study suggested that LVH pre-KT, ventricular dilatation, and systolic dysfunction were associated with higher all-cause mortality and CV mortality after KT (59) . Concerning DD specifically less is known. One study evaluated the impact of pretransplant LA dilation and LVH, markers of fluid status and DD, on survival after successful KT and concluded that they are significant, independent predictors of death in patients who proceed with KT (61) .
Although there is a significant improvement in LVDD after KT, the existence of DD previous to KT confers an increased risk of cardiovascular mortality. Thus, the management and screening for diabetes, hypertension, obesity, dyslipidemia, tobacco use, and other contributing or concurrent conditions addressed in the previous section is mandatory in the KT population as well (62) .
STUDIES REPORTING DD IN DIALYSIS POPULATIONS
Finally, with respect to the published studies evaluating HFpEF in dialysis, there is, to the best of our knowledge, few studies. Antlanger et al. analyzed 105 maintenance HD patients about prevalence, associations with clinical characteristics, and prognosis of HFpEF. Ninety-six percent had evidence of DD and 70% of the entire cohort fulfilled HF criteria (81% HFpEF vs. 19 % HFrEF). Age, female sex, body mass index, blood pressure, and dialysis vintage were predictive of HFpEF (63) . In another study, Barberato et al. evaluated the prevalence and prognostic impact of LV advanced diastolic dysfunction (ADD) in patients on HD using echocardiography. A total of 129 patients with a DD prevalence of 73% (50% with mild DD and 23% with ADD) were included in the study. The group with ADD was older, presented higher systolic and diastolic BP, LV mass, LA volume index and number of diabetic patients, as well as lower EF. After 17 AE 7 months, the general mortality was significantly higher in individuals with ADD, when compared to those with normal function and mild DD. In conclusion, DD was very prevalent (73%) and ADD had a prognostic impact, regardless of other clinical and echocardiographic data (64) . Instead, Wang et al. aimed to determine the prevalence, clinical profiles, and long-term outcomes of PD patients with HFpEF. A prospective cohort study with 220 patients were treated with peritoneal dialysis. Eighty-six (39%) patients had HF, of whom 54.7% had preserved EF ≥50% and 45.3% had reduced EF <50%. Patients with HFpEF were intermediate between those with no HF and those with HFrEF in terms of blood pressure, prevalence of coronary artery disease, diabetes, cardiac biomarkers, LV mass, volume, and ratio of early mitral inflow velocity to peak mitral annulus velocity. In the multivariable Cox regression analysis, patients with HFpEF showed an increased adjusted Hazard Ratio (HR) for cardiac, HF and fatal or nonfatal cardiovascular event compared with those with no HF, but the risk was lower compared with those with HFrEF, indicating that HFpEF is associated with increased risk of mortality and adverse cardiovascular outcomes compared with those with no HF, although the risk was lower than in patients with HFrEF (1).
CONCLUSIONS
Heart failure with preserved ejection fraction (HFpEF) in CKD and ESRD is underdiagnosed. It requires updated diagnostic criteria and if misdiagnosed is more frequent than heart failure with reduced ejection fraction (HFrEF). However, the classical pharmacological measures that change survival in HFrEF cannot be applied in patients with HFpEF, so that pharmacological strategies improving diastolic dysfunction (DD) are lacking.
Rigorous control of blood pressure, best achieved by intravascular volume depletion, is very important. Rigorous salt restriction and ultrafiltration are both required to bring volume overexpansion and elevated blood pressure under better control. Correction of anemia plays only a minor role in ameliorating HFpEF. Conventional thrice-weekly, short-duration HD are both manifestly inadequate for control of HFpEF in the majority of patients with ESRD. More frequent and longer HD regimens are likely to be the best strategy for control of the dangerous complication of left ventricular hypertrophy (LVH) in ESRD. Prevention of fatal arrhythmias may be approached using a cardioselective beta-blockers in patients with severe HFpEF, but much more basic and clinical research is needed to bring more and better pharmacologic ways of abrogating HFpEF and its consequences. Additional research and clinical trials will be needed to bring new pharmacologic approaches for control of HFpEF. Control of LVH should be at the core of management of CKD and ESRD. In order to achieve this change, a new mindset will have to arise among nephrologists and a new paradigm of care will have to be diligently applied to the care of patients with CKD and ESRD.
Much more research and clinical trials are needed before a definite role can be established for treatment (or prevention) of LVH and/or cardiac fibrosis with analogs of vitamin D, cinacalcet, aldosterone antagonists, direct renin inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. Nevertheless, experimental data and limited clinical studies support the use of these agents as potential candidates for pharmacological manipulation to reduce the risk of LVH in CKD and ESRD.
Very clearly, patients with CKD and ESRD should be monitored regularly (perhaps every 1-2 years) for the development and assessment of the severity of LVH and cardiac fibrosis, most likely with serial echocardiography.
